Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals announced that four abstracts evaluating PEDMARK have been accepted for presentation at the 2026 ASCO Annual Meeting. The accepted abstracts feature data from the Japanese Children’s Cancer Group STS-J01 study and a randomized Phase 1 trial at City of Hope, highlighting the drug's application in pediatric and young adult populations.
Key figures
- Drug Name
- PEDMARK
- Phase Of Trial
- Phase 1, Phase 3
- Abstract count
- 4
- Ototoxicity incidence range
- 60-90%
- Annual us platinum diagnoses
- 500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.